Assignee
I MAB BIOPHARMA US LTD
US·12 granted patents·8 pending applications·11 citations·filing 2019–2023
Top patents by PatentIndex Score
20 records- 0188US11034771B2Anti-CD73 anti-PD-L1 bispecific antibodiesI MAB BIOPHARMA US LTD·Filed 2019·Granted Jun 15, 2021·9 cites·23 claims
- 0282US11261259B2Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 1, 2022·1 cites·19 claims
- 0373US11401331B2Anti-PD-L1 antibody and IL-7 fusionsI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 2, 2022·1 cites·6 claims
- 0467US11613577B2Anti-CD73 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Mar 28, 2023·0 cites·8 claims
- 0567US2020317789A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 0666US12577313B2Anti-claudin 18.2 and anti-4-1BB bispecific antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2022·Granted Mar 17, 2026·0 cites·15 claims
- 0766US2022119531A1Anti-pd-l1 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 0865US12091467B2CD47 monoclonal antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2020·Granted Sep 17, 2024·0 cites·4 claims
- 0965US11414485B2Anti-LAG-3 antibodies and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Aug 16, 2022·0 cites·14 claims
- 1063US11059897B2Anti-IFNAR1 antibodies for treating autoimmune diseasesI MAB BIOPHARMA US LTD·Filed 2019·Granted Jul 13, 2021·0 cites·15 claims
- 1163US2025163150A1Combination therapies comprising a kras inhibitor for the treatment of cancerI MAB BIOPHARMA US LTD·Filed 2023·Application pending·0 cites
- 1260US12145982B2Anti-CXCL13 antibodies for treating autoimmune diseases and cancerI MAB BIOPHARMA US LTD·Filed 2021·Granted Nov 19, 2024·0 cites·19 claims
- 1359US11028164B2Anti-CXCL13 antibodiesI MAB BIOPHARMA US LTD·Filed 2019·Granted Jun 8, 2021·0 cites·14 claims
- 1456US2020407441A1Fusion Proteins Containing CD48 Antibodies and CytokinesI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
- 1555US2023393144A1Methods for mitigating interference by therapeutic anti-cd47 antibodies in pre-transfusion assaysI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 1654US2023174649A1Pharmaceutical compositions containing anti-cd47 antibodiesI MAB BIOPHARMA US LTD·Filed 2021·Application pending·0 cites
- 1751US11208486B2Human PD-L1 antibodiesI MAB BIOPHARMA US LTD·Filed 2020·Granted Dec 28, 2021·0 cites·18 claims
- 1851US10973853B2Antibodies to T cell immunoreceptor with IG and ITIM domains (TIGIT) and uses thereofI MAB BIOPHARMA US LTD·Filed 2019·Granted Apr 13, 2021·0 cites·7 claims
- 1950US2022112258A1Bifunctional molecules with il-7 activityI MAB BIOPHARMA US LTD·Filed 2020·Application pending·0 cites
- 2049US2021269522A1Novel CD47 Antibodies and Methods of Using SameI MAB BIOPHARMA US LTD·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when I MAB BIOPHARMA US LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →